Therapeutic drug monitoring (TDM) of clozapine and norclozapine

Therapeutic drug monitoring (TDM) is the practice of measuring a drug's concentration in the blood to guide dosing. For most antipsychotics, TDM is optional and uncommon. For clozapine, it is one of the highest-value tools available — clozapine has a clear concentration-response relationship, an enormous interpatient variability in metabolism, and many factors that change levels over time. Knowing your number changes how you and your prescriber think about your dose.

Why clozapine TDM is so useful

• Wide variability — two patients on the same dose can have plasma levels that differ tenfold because of differences in CYP1A2 metabolism, smoking, weight, age, and sex.
• Threshold response — a substantial body of evidence suggests that clozapine is more likely to work above a plasma threshold of about 350 ng/mL.
• Toxicity ceiling — levels above 1,000 ng/mL increase the risk of seizures, sedation, and other side effects.
• Adherence check — levels can confirm whether a patient is taking the medication.
• Smoking changes — quitting smoking can roughly double clozapine levels; restarting can halve them. This is a major safety issue around hospital admissions.

What the assay measures

Most clozapine assays report:

• Clozapine — the parent drug, the main contributor to antipsychotic effect
• Norclozapine (N-desmethylclozapine) — the major metabolite, with its own pharmacological activity
• Clozapine + norclozapine total — sometimes reported
• Clozapine/norclozapine ratio — usually around 1.3–2.0; can give clues about metabolism speed and adherence

When to check

Clozapine TDM is reasonable in the following situations:

• Once a stable maintenance dose has been reached, to document a baseline level
• When the patient is not responding clinically despite an apparently adequate dose
• When side effects appear out of proportion to the dose
• After dose changes (allow at least 5–7 days at the new dose)
• After starting or stopping smoking
• After starting or stopping interacting medications (fluvoxamine, ciprofloxacin, certain hormonal contraceptives)
• After significant weight changes
• After acute illness that may suppress CYP enzymes (severe infection, inflammation)
• When adherence is uncertain

How to draw the level correctly

The standard is a trough level:

• Drawn 12 hours after the last dose (typically morning, before the morning dose)
• At steady state — at least 5–7 days on the current total daily dose
• Note the dose, time of last dose, smoking status, recent illnesses, and concurrent medications on the order

A level drawn at the wrong time (too soon after a dose, too long after) is hard to interpret and may need to be repeated.

Target ranges

The most commonly cited threshold for response in treatment-resistant schizophrenia is 350 ng/mL, supported by multiple studies. Some authors propose 250 ng/mL as a lower bound and emphasise individual variation. A practical interpretation:

• < 250 ng/mL: typically subtherapeutic for refractory psychosis
• 250–350 ng/mL: borderline; some patients respond, others need more
• 350–600 ng/mL: usual therapeutic range
• 600–1,000 ng/mL: higher therapeutic range; sometimes needed
• > 1,000 ng/mL: increased risk of seizures, sedation, cardiac effects; usually warrants dose reduction unless clearly needed

What changes the level

Smoking

Tobacco smoke induces CYP1A2, the main enzyme that metabolises clozapine. Smokers typically need higher doses to reach the same plasma level. Quitting can roughly double clozapine levels within 2–4 weeks, sometimes producing toxicity. This is a critical issue when patients are admitted to non-smoking psychiatric units.

Caffeine

Heavy caffeine intake can increase clozapine levels modestly through CYP1A2 inhibition. See our caffeine and clozapine article.

Drug interactions

• Fluvoxamine can raise clozapine levels several-fold via potent CYP1A2 inhibition
• Ciprofloxacin is a moderate CYP1A2 inhibitor
• Estrogen-containing contraceptives can raise levels via CYP1A2 inhibition
• Carbamazepine, phenytoin, rifampin, St John's wort can lower levels via enzyme induction

Inflammation and infection

Acute infection or inflammation transiently suppresses CYP1A2. Clozapine levels can rise sharply during severe infection, occasionally reaching toxic levels. Patients with new infection on clozapine should be monitored carefully.

Sex and age

Women generally have higher clozapine levels per dose than men. Older adults clear it more slowly than younger adults.

The clozapine/norclozapine ratio

The ratio is usually around 1.3–2.0 at steady state. Very high ratios (over 3) can suggest CYP1A2 inhibition (e.g., from smoking cessation) or a recent large dose. Very low ratios may suggest induction or, in some cases, non-adherence with a dose taken just before the lab draw.

What TDM does not tell you

• It does not tell you whether the patient will respond — some patients respond at 300 ng/mL, some need 700.
• It does not replace clinical assessment of symptoms, side effects, and function.
• It does not tell you about clozapine's other risks (myocarditis, neutropenia, constipation) directly.

Practical questions to ask your prescriber

• What was my last clozapine level, and when was it drawn?
• Where am I in the target range?
• How does my smoking status affect my number?
• Should we recheck after this dose change?

The big picture

Clozapine TDM is one of the most useful tools in psychiatric pharmacology. The test is not expensive, the target range is reasonably well established, and the variables that affect levels — smoking, infections, interacting drugs — are knowable and trackable. For patients on clozapine, knowing your number is part of being an active participant in your own care.

This article is for educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a qualified mental health professional. If you or someone you know is in crisis, call or text 988 in the US, or your local emergency number.